期刊
MAYO CLINIC PROCEEDINGS
卷 95, 期 6, 页码 1213-1221出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2020.03.024
关键词
-
资金
- Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program
As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the ?off -label ? repurposing of drugs such as hydroxy- chloroquine and lopinavir/ritonavir, which have the potential for unwanted QT -interval prolongation and a risk of drug -induced sudden cardiac death. With the possibility that a considerable proportion of the world ?s population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug -induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据